A web-based tool for adjusting costs to a specific target currency and price year

Shemilt, Ian; Thomas, James; Morciano, Marcello

doi:10.1332/174426410x482999

Cited by 275 publications

(254 citation statements)

References 0 publications

Supporting

Mentioning

182

Contrasting

Unclassified

Order By: Relevance

“…Data extraction was conducted by AB and queries resolved through discussion with JM. All costs were converted to 2013 US dollars (US$) by applying the GDP deflator index and purchasing power parities conversion rate to compare the CEA of the included studies using CCEMG-Evidence for Policy and Practice Information and Coordinating Centre (EPPI-Centre) Cost Converter (V1.4) (Shemilt et al 2010). …”

Section: Data Extraction and Analysismentioning

confidence: 99%

Cost-effectiveness of interventions to prevent road traffic injuries in low- and middle-income countries: A literature review

Banstola

Mytton

2016

Traffic Injury Prevention

View full text Add to dashboard Cite

Section: Data Extraction and Analysismentioning

confidence: 99%

Cost-effectiveness of interventions to prevent road traffic injuries in low- and middle-income countries: A literature review

Banstola

Mytton

2016

Traffic Injury Prevention

View full text Add to dashboard Cite

“…3 Eczema also has a substantial cost impact on society and the individual families affected; for example, the total annual UK cost of eczema in children aged ≤ 5 years is estimated to be £70.6M (or £120.19 per child) (inflated from 1996 to 2015 price year), 45 of which 64% was accounted for by NHS health-care costs. 46 A further UK study looking at patients of all ages estimated the total annual cost of eczema for the UK to be in the order of £726.7M, of which £195.3M was incurred by the NHS, £464.1M by the patients and £67.2M by society in terms of lost working days (inflated from 1995 to 2015 price year; 45 original price year not reported but most likely to be 1995). 47 Core eczema treatment involves the regular use of emollients and topical corticosteroid creams.…”

Section: Introductionmentioning

confidence: 99%

Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial

Kim

Bradshaw

Sach

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

Background: Atopic eczema (AE) is a chronic, itchy, inflammatory skin condition that affects the quality of life of children and their families. The role of specialist clothing in the management of AE is poorly understood.Objectives: To assess the effectiveness and cost-effectiveness of silk garments for the management of AE in children with moderate to severe disease.Design: Parallel-group, observer-blind, randomised controlled trial of 6 months’ duration, followed by a 2-month observational period. A nested qualitative study evaluated the beliefs of trial participants, health-care professionals and health-care commissioners about the use of silk garments for AE.Setting: Secondary care and the community in five UK centres.Participants: Children aged 1–15 years with moderate or severe AE.Interventions: Participants were randomised (1 : 1 using online randomisation) to standard care or standard care plus 100% silk garments made from antimicrobially protected knitted sericin-free silk [DermaSilkTM (AlPreTec Srl, San Donà di Piave, Italy) or DreamSkinTM (DreamSkin Health Ltd, Hatfield, UK)]. Three sets of garments were supplied per participant, to be worn for up to 6 months (day and night). At 6 months the standard care group received the garments to use for the remaining 2-month observational period.Main outcome measures: Primary outcome – AE severity using the Eczema Area and Severity Index (EASI) assessed at 2, 4 and 6 months, by nurses blinded to treatment allocation. EASI scores were log-transformed for analysis. Secondary outcomes – patient-reported eczema symptoms (Patient Oriented Eczema Measure); global assessment of severity (Investigator Global Assessment); quality of life of the child (Atopic Dermatitis Quality of Life, Child Health Utility – 9 Dimensions), family (Dermatitis Family Impact Questionnaire) and main carer (EuroQoL-5 Dimensions-3 Levels); use of standard eczema treatments (e.g. emollients, topical corticosteroids); and cost-effectiveness. The acceptability and durability of the clothing, and adherence to wearing the garments, were assessed by parental/carer self-report. Safety outcomes – number of skin infections and hospitalisations for AE.Results: A total of 300 children were randomised (26 November 2013 to 5 May 2015): 42% female, 79% white, mean age 5 years. The primary analysis included 282 out of 300 (94%) children (n = 141 in each group). Garments were worn for at least 50% of the time by 82% of participants. Geometric mean EASI scores at baseline, 2, 4 and 6 months were 8.4, 6.6, 6.0, 5.4 for standard care and 9.2, 6.4, 5.8, 5.4 for silk clothing, respectively. There was no evidence of difference between the groups in EASI score averaged over all follow-up visits adjusted for baseline EASI score, age and centre (ratio of geometric means 0.95, 95% confidence interval 0.85 to 1.07; p = 0.43). This confidence interval is equivalent to a difference of –1.5 to 0.5 in the original EASI scale units. Skin infections occurred in 39 out of 141 (28%) and 36 out of 142 (25%) participants for sta...

show abstract

“…To avoid double counting the bed day cost (which was included in the estimation of opportunity cost PI discussed below), we removed it from the treatment cost per case. All costs in UK 2011 prices were converted to Australian 2012-13 prices using the web tool by Shemilt et al 44 (see Table 1). The stage-specific cost per case was generated from a uniform distribution with the minimum and maximum values specified as AE10% of the average cost per stage.…”

Section: Average Treatment Cost Of Each Pi Stagementioning

confidence: 99%

Pressure injury in Australian public hospitals: a cost-of-illness study

Nguyen

Chaboyer²,

Whitty

2015

Aust. Health Review

144

102

View full text Add to dashboard Cite

Objective. Pressure injuries (PI) are largely preventable and can be viewed as an adverse outcome of a healthcare admission, yet they affect millions of people and consume billions of dollars in healthcare spending. The existing literature in Australia presents a patchy picture of the economic burden of PI on society and the health system. The aim of the present study was to provide a more comprehensive and updated picture of PI by state and severity using publicly available data.Methods. A cost-of-illness analysis was conducted using a prevalence approach and a 1-year time horizon based on data from the existing literature extrapolated using simulation methods to estimate the costs by PI severity and state subgroups.Results. The treatment cost across all states and severity in 2012-13 was estimated to be A$983 million per annum, representing approximately 1.9% of all public hospital expenditure or 0.6% of the public recurrent health expenditure. The opportunity cost was valued at an additional A$820 million per annum. These estimates were associated with a total number of 121 645 PI cases in 2012-13 and a total number of 524 661 bed days lost.Conclusions. The costs estimated in the present study highlight the economic waste for the Australian health system associated with a largely avoidable injury. Wastage can also be reduced by preventing moderate injuries (Stage I and II) from developing into severe cases (Stage III and IV), because the severe cases, accounting for 12% of cases, mounted to 30% of the total cost. What is known about the topic?The literature has identified that in the Australian health care system, wound management is one of the most frequently performed procedures. However, the overall economic cost of PI to the public hospital system is largely unknown. What does this paper add? This study provides reliable estimates, based predominantly on Australian data, of the number of cases and treatment costs associated with PI in public hospitals, disaggregated by state and severity. The paper also attempts to quantify the opportunity cost of PI, which leads to extra hospital length of stay. The estimated costs give an indication of the economic waste to the health system due to avoidable injury. What are the implications for practitioners? This study is relevant and important in the context of rising healthcare costs. It highlights an area for potential improvement in quality of care (i.e. better hospital experience for patients) and efficiency (i.e. reducing economic waste) in the hospital sector. It also reveals the paucity of data available to support cost estimation, from the prevalence and incidence rates to the treatment cost by disease severity, which further highlights an under-researched area.

show abstract

A web-based tool for adjusting costs to a specific target currency and price year

Cited by 275 publications

References 0 publications

Cost-effectiveness of interventions to prevent road traffic injuries in low- and middle-income countries: A literature review

Cost-effectiveness of interventions to prevent road traffic injuries in low- and middle-income countries: A literature review

Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial

Pressure injury in Australian public hospitals: a cost-of-illness study

Contact Info

Product

Resources

About